These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22845019)

  • 1. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
    Leal I; Romio SA; Schuemie M; Oteri A; Sturkenboom M; Trifirò G
    Br J Clin Pharmacol; 2013 Mar; 75(3):861-8. PubMed ID: 22845019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
    Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
    Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
    Hall GC; Smith HT; Curtis B; McMahon AD
    Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on: prescribing of rosiglitazone and pioglitazone following safety signals analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008.
    Carracedo-Martínez E
    Drug Saf; 2014 Dec; 37(12):1069-70. PubMed ID: 25249047
    [No Abstract]   [Full Text] [Related]  

  • 7. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM; Taylor TN; Jaber LA
    Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
    Colhoun HM; Livingstone SJ; Looker HC; Morris AD; Wild SH; Lindsay RS; Reed C; Donnan PT; Guthrie B; Leese GP; McKnight J; Pearson DW; Pearson E; Petrie JR; Philip S; Sattar N; Sullivan FM; McKeigue P;
    Diabetologia; 2012 Nov; 55(11):2929-37. PubMed ID: 22945303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Author's reply to Carracedo-Martínez E comment on: "prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008".
    Stricker BH
    Drug Saf; 2014 Dec; 37(12):1071. PubMed ID: 25249048
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
    Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.
    Hsu JC; Cheng CL; Ross-Degnan D; Wagner AK; Zhang F; Kao Yang YH; Liu LL; Tai HY; Chen KH; Yang PW; Lu CY
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1026-35. PubMed ID: 26251229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.
    Stewart KA; Natzke BM; Williams T; Granger E; Casscells SW; Croghan TW
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1048-52. PubMed ID: 19655338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
    Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
    Niyomnaitham S; Page A; La Caze A; Whitfield K; Smith AJ
    BMC Health Serv Res; 2014 Apr; 14():151. PubMed ID: 24708579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
    Jain R; Mullins CD; Lee H; Wong W
    Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
    Breunig IM; Shaya FT; McPherson ML; Snitker S
    J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
    Punthakee Z; Bosch J; Dagenais G; Diaz R; Holman R; Probstfield J; Ramachandran A; Riddle M; Rydén LE; Zinman B; Afzal R; Yusuf S; Gerstein H;
    Diabetologia; 2012 Jan; 55(1):36-45. PubMed ID: 22038523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones.
    Hashim S; Gomes T; Juurlink D; Hellings C; Mamdani M
    J Popul Ther Clin Pharmacol; 2013; 20(3):e238-42. PubMed ID: 24141901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.